Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and SCH66336 in Recurrent and Progressive Glioblastoma Multiforme
NCT00038493Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2001
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lonafarnib in glioblastoma multiforme (GBM), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2001; status: completed.
02
Drugs
lonafarnib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00038493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038493.